Ab Initio CSO, Dr Hui Xin Ong, to give RDD podium on preclinical tools

Dr Hui Xing Ong (YY), Ab Initio’s Chief Scientific Officer, will present on the podium at RDD2022. YY Will update you on recent advances in preclinical screening tools that can be used to evaluate the saftey, efficacy and pharmacokinetics of new medicines. Using these micro fluidic platforms, real inhalation formulations can be evaluated in real-time,. overcoming issues with traditional cell biology approaches. Join us in person, to listen to YY on the 2nd May at 1030am live from Orlando, Florida.